Literature DB >> 11282552

Analysis of interleukin-18, interleukin-1 converting enzyme (ICE) and interleukin-18-related cytokines in Crohn's disease lesions.

F Pagès1, V Lazar, A Berger, C Danel, S Lebel-Binay, F Zinzindohoué, P Desreumaux, C Cellier, N Thiounn, D Bellet, P H Cugnenc, W H Fridman.   

Abstract

A local increase of interleukin-18 (IL-18) expression has been recently demonstrated in Crohn's disease (CD), suggesting a role for mature IL-18 (cleaved by ICE protease) in the induction of proinflammatory cytokines and Th1 polarization observed in CD lesions. The aim of this study was to investigate IL-18 modulation and its potential immune consequences in CD lesions. We showed increased IL-18 production in chronic CD lesions and identified epithelial cells and macrophages as IL-18-producing cells. A twofold increase in ICE alpha, beta, and/or gamma mRNA that encodes for the complete mature peptide was required for ICE activity, and a marked increase in IL-18R-positive immune cells was observed in chronic lesions compared to uninvolved areas or normal control samples. Chronic lesions also displayed intense transcription of IL-18-induced cytokines, IFN-gamma, IL-1beta, TNF-alpha, and IL-8. By contrast, when neither IL-18 nor ICE mRNAs were enhanced (early asymptomatic CD lesions), IL-18-induced cytokines were not up-regulated. These results are in accordance with a putative role of mature IL-18 in the pathogenesis of CD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11282552

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  8 in total

1.  [Effects of recombinant fusion protein interleukin-18 on expression of immune-inflammatory factors in mice infected with Staphylococcus aureus].

Authors:  Chen Chen; Qiang Chen; Lan Li; Xiao-Jun Yu; Jiang-Wei Ke; Mei-Juan He; Hong-Ping Zhou; Wen-Ping Yang; Wen-Xing Wang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-06

Review 2.  Role of cytokines in inflammatory bowel disease.

Authors:  Fausto Sanchez-Munoz; Aaron Dominguez-Lopez; Jesus-K Yamamoto-Furusho
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

3.  Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models.

Authors:  P Maerten; C Shen; S Colpaert; Z Liu; D A M Bullens; G van Assche; F Penninckx; K Geboes; G Vanham; P Rutgeerts; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

4.  Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease.

Authors:  Andreas Stallmach; Thomas Giese; Carsten Schmidt; Bianca Ludwig; Ina Mueller-Molaian; Stefan C Meuer
Journal:  Int J Colorectal Dis       Date:  2003-11-07       Impact factor: 2.571

5.  Administration of exogenous interleukin-18 and interleukin-12 prevents the induction of oral tolerance.

Authors:  Alfred D Eaton; Damo Xu; Paul Garside
Journal:  Immunology       Date:  2003-02       Impact factor: 7.397

6.  IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease.

Authors:  Paola Bossù; Detlef Neumann; Elda Del Giudice; Antonio Ciaramella; Isabelle Gloaguen; Giamila Fantuzzi; Charles A Dinarello; Emma Di Carlo; Piero Musiani; Pier Luigi Meroni; Gianfranco Caselli; Paolo Ruggiero; Diana Boraschi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-13       Impact factor: 11.205

7.  Effects of ex-vivo and in-vivo treatment with probiotics on the inflammasome in dogs with chronic enteropathy.

Authors:  Silke Schmitz; Dirk Werling; Karin Allenspach
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

8.  Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines.

Authors:  Amarjargal Dashdorj; K R Jyothi; Sangbin Lim; Ara Jo; Minh Nam Nguyen; Joohun Ha; Kyung-Sik Yoon; Hyo Jong Kim; Jae-Hoon Park; Michael P Murphy; Sung Soo Kim
Journal:  BMC Med       Date:  2013-08-06       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.